High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Protagonist Therapeutics (NASDAQ:PTGX) said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera, or PV. The approval marks the company’s second FDA-approved medicine this year, following the M
Some companies have handed investors a bigger paycheck every single year for more than six decades, surviving every recession and rate shock along the way. Five of them look particularly compelling right now, and one trades at a price not seen in over a year.
The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.
Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is whether this momentum can last.
Wall Street is set to open higher on Thursday as strong Microsoft results helped technology stocks recover from their sharp post-Federal Reserve sell-off. Dow Jones futures were up 225 points, or 0.4%, while S&P 500 futures pointed to a 0.6% gain and the Nasdaq was called 1.3%...
July 29 () - GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its diagnostic and imaging devices and refunds of tariffs imposed under U. Shares of the medical device maker rose 12% in premarket trading.
July 29 (Reuters) - GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its diagnostic and imaging devices and refunds of tariffs imposed
The U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson’s OTTAVA Robotic Surgical System, marking the regulatory clearance of the world’s first table-integrated soft tissue robotic platform. The marketing clearance encompasses multiple general surgery...
By Puyaan Singh July 22 (Reuters) - Johnson & Johnson said on Wednesday the U.S.
J&J has more than 28 sources of blockbuster revenue.
Investors didn't seem to think so after the company published it.
Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...
The healthcare company posted $25.31 billion in quarterly sales and raised its annual sales forecast to about $101.1 billion at the midpoint
Johnson & Johnson (NYSE:JNJ) reported stronger-than-expected second-quarter results and raised its full-year earnings outlook, although the healthcare company’s shares slipped around 1 percent in premarket trading on Wednesday. Earnings and revenue beat expectationsThe company posted adjusted earnings per share of 2.
Investing.com -- Johnson & Johnson (NYSE:JNJ) reported second-quarter results that exceeded Wall Street expectations, though shares are down around 1% premarket on Wednesday.
By Michael Erman July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster
Stocks looked set to rise again on Wednesday, building on gains from the previous session that were powered by a solid start to the second-quarter earnings season and cooler-than-expected inflation data. Nasdaq 100 futures added 0.4%. Dow Jones Industrial Average futures rose 81 points, or 0.2%.
Fundstrat’s Tom Lee returned to CNBC’s Morning Call Sheet on Thursday, July 9, alongside JonesTrading’s Mike O’Rourke and Vital Knowledge’s Adam Crisafulli, to discuss a market that is simultaneously celebrating the AI build-out while rotating into value and defensive names. Lee argued: “AI is probably one of the most important structural stories in our lifetime.” ... Fundstrat’s Tom Lee: AI Is a Once in a Lifetime Story – Why Easing Inflation in H2 2026 Could Fuel the Next Rally
Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.
Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.
Most drivers replace their vehicles the same way: make payments for a few years, trade the car in, then start the cycle over again. A portfolio can break that cycle by generating enough income to fund future replacements. With the average new vehicle now costing roughly $48,000 to $49,000 and inflation continuing to push prices ... The Portfolio That Buys You A New Car Every Three Years
A 65-year-old retiree with $1 million who follows the standard 4% rule withdraws $40,000 in the first year, then increases that amount over time to keep pace with inflation. A dividend-focused alternative starts slightly lower, at about $38,000 in annual income from a 3.8% blended yield, but does not require selling shares. Over 20 years, ... The Dividend Strategy That Beats the 4% Rule by $400,000 Over 20 Years on a $1 Million Portfolio
Johnson & Johnson has agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that bolsters the drugmaker’s oncology pipeline.
June 8 (Reuters) - Johnson & Johnson said on Monday it will acquire biotech Firefly Bio for $1 billion in cash, as it looks to expand its cancer drug pipeline.
Shares of Medtronic jumped 5% Wednesday after the medical-device maker reported better-than-expected quarterly results, helped by strong sales of devices used in heart procedures. The company also said it applied for U.
A traditional defined-benefit pension paying $5,500 per month, or $66,000 annually, provides a useful retirement-income benchmark. That level of income sits near the upper range of what many private-sector pensions deliver, and it represents the amount a 67-year-old married couple would need to recreate if offered a lump-sum payout instead of guaranteed monthly checks for ... A Monthly Dividend Portfolio That Pays Like a Pension and Beats Most Pensions on Inflation Protection
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
